Can albuterol (salbutamol) be used, including a rescue dose up to 30 minutes before a regadenoson stress test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Albuterol Be Used Before a Regadenoson Stress Test?

Yes, albuterol (salbutamol) can be used as a rescue medication up to 30 minutes before a regadenoson stress test, though it should ideally be withheld for at least 4 hours prior to testing when possible.

Key Recommendation

The FDA label for regadenoson does not list albuterol as a contraindication or require its discontinuation before testing 1. However, standard spirometry and bronchoprovocation testing guidelines recommend withholding short-acting β-agonists like albuterol for 4 hours before pulmonary function testing to avoid interference with baseline measurements 2.

Clinical Context and Rationale

For patients with reactive airway disease undergoing regadenoson stress testing:

  • Regadenoson is safer than adenosine in patients with mild-to-moderate reactive airway disease because it is a selective A2A adenosine receptor agonist with minimal A1, A2B, and A3 receptor stimulation, thereby reducing the risk of bronchospasm compared to non-selective adenosine 3

  • Bronchospasm risk is reduced but not eliminated - regadenoson can still cause dyspnea (28% of patients) and rarely bronchospasm, particularly in patients with severe COPD 1, 4

  • Aminophylline is the primary reversal agent for regadenoson-induced adverse effects, not albuterol. The FDA label recommends aminophylline 50-250 mg IV over 30-60 seconds for persistent adverse effects 1

Practical Algorithm

If the patient requires albuterol within 4 hours of testing:

  1. Assess severity of respiratory symptoms - if the patient needs rescue albuterol within 4 hours of the scheduled test, their asthma/COPD may not be optimally controlled
  2. Consider rescheduling if symptoms suggest poor disease control
  3. If testing must proceed:
    • Administer albuterol as needed for acute symptoms
    • Document the timing and dose
    • Proceed with regadenoson stress test
    • Have aminophylline readily available (not albuterol) for reversal of regadenoson effects 1

For planned rescue dosing 30 minutes before:

  • This is not standard practice and lacks evidence support
  • The 4-hour washout period from spirometry guidelines 2 suggests albuterol effects could still be present at 30 minutes
  • If bronchodilation is needed this close to testing, reconsider whether the patient is stable enough for pharmacologic stress

Important Caveats

Contraindications to regadenoson that should prompt alternative testing:

  • Severe COPD with active bronchospasm
  • Second- or third-degree AV block without a functioning pacemaker
  • Sinus node dysfunction without a pacemaker
  • Systolic blood pressure <90 mmHg 1

Methylxanthine interference:

  • Caffeine and theophylline are adenosine receptor antagonists that significantly reduce regadenoson's vasodilatory effect (60% reduction in reversible defect detection with 200-400 mg caffeine) 1
  • Patients should avoid caffeine for at least 12 hours before testing 1
  • However, albuterol is a β-agonist, not a methylxanthine, and does not directly antagonize adenosine receptors

Safety profile in severe COPD:

  • Studies show regadenoson combined with low-level exercise is safe in stable severe COPD patients, with self-limiting dyspnea (33%) and no clinical COPD exacerbations 4
  • This suggests that patients on maintenance bronchodilators can safely undergo regadenoson stress testing

References

Guideline

standardisation of spirometry.

European Respiratory Journal, 2005

Research

Regadenoson: a new myocardial stress agent.

Journal of the American College of Cardiology, 2009

Research

Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.

Revista espanola de medicina nuclear e imagen molecular, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.